Juvenile dermatomyositis

Handbook of Clinical Neurology

Volumn 113, Issue , 2013, Pages 1457-1463

  Quartier, Pierre ^a   Gherardi, Romain K ^b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84876872226     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-444-59565-2.00014-9     Document Type: Chapter

References (48)

1. Adams E.M., Chow C.K., Premkumar A., et al. The idiopathic inflammatory myopathies: spectrum of MR imaging findings. Radiographics 1995, 15:563-574.
2. Al-Mayouf S., Al-Mazyed A., Bahabri S. Efficacy of early treatment of severe juvenile dermatomyositis with intravenous methylprednisolone and methotrexate. Clin Rheumatol 2000, 19:138-141.
3. Alsufyani K.A., Ortiz-Alvarez O., Cabral D.A., et al. Bone mineral density in children and adolescents with systemic lupus erythematosus, juvenile dermatomyositis, and systemic vasculitis: relationship to disease duration, cumulative corticosteroid dose, calcium intake, and exercise. J Rheumatol 2005, 32:729-733.
4. Baechler E.C., Bauer J.W., Slattery C.A., et al. An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity. Mol Med 2007, 13:59-68.
5. Bingham A., Mamyrova G., Rother K.I., et al. Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity. Medicine (Baltimore) 2008, 87:70-86.
6. Bode R.K., Klein-Gitelman M.S., Miller M.L., et al. Disease activity score for children with juvenile dermatomyositis: reliability and validity evidence. Arthritis Rheum 2003, 49:7-15.
7. Bohan A., Peter J.B. Polymyositis and dermatomyositis. N Engl J Med 1975, 292:403-407.
8. Bowyer S.L., BLane C.E., Sullivan D.B., et al. Childhood dermatomyositis: factors predicting functional outcome and development of dystrophic calcification. J Pediatr 1983, 103:882-888.
9. Cassidy J.T., Petty R.E. Juvenile dermatomyositis. Textbook of Pediatric Rheumatology 2001, 465-504. WB Saunders, Philadelphia. 4th edn. J.T. Cassidy, R.E. Petty (Eds.).
10. Compeyrot-Lacassagne S., Feldman B.M. Inflammatory myopathies in children. Pediatr Clin North Am 2005, 52:493-520.
11. Cooper M.A., Willingham D.L., Brown D.E., et al. Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients. Arthritis Rheum 2007, 56:3107-3111.
12. Edge J.C., Outland J.D., Dempsey J.R., et al. Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis. Arch Dermatol 2006, 142:65-69.
13. Englund P., Nennesmo I., Klareskog L., et al. Interleukin-1alpha expression in capillaries and major histocompatibility complex class I expression in type II muscle fibers from polymyositis and dermatomyositis patients: important pathogenic features independent of inflammatory cell clusters in muscle tissue. Arthritis Rheum 2002, 46:1044-1055.
14. Feldman B.M., Ayling-Campos A., Luy L., et al. Measuring disability in juvenile dermatomyositis: Validity of the childhood health assessment questionnaire. J Rheumatol 1995, 22:326-331.
15. Feldman B.M., Rider L.G., Reed A.M., et al. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet 2008, 371:2201-2212.
16. Fraser D.D., Frank J.A., Dalakas M., et al. Magnetic resonance imaging in the idiopathic inflammatory myopathies. J Rheumatol 1991, 18:1693-1700.
17. Gardner-Medwin J.M., Irwin G., Johnson K. MRI in juvenile idiopathic arthritis and juvenile dermatomyositis. Ann N Y Acad Sci 2009, 1154:52-83.
18. Heckmatt J., Hasson N., Saunders C., et al. Cyclosporin in juvenile dermatomyositis. Lancet 1989, 1:1063-1066.
19. Hicks J., Wesley R., Koziol D., et al. Validation of manual muscle testing in the assessment of juvenile dermatomyositis. Arthritis Rheum 2000, 43:S194.
20. Hollar C.B., Jorizzo J.L. Topical tacrolimus in treatment for refractory skin disease in dermatomyositis: a pilot study. J Dermatolog Treat 2004, 15:35-39.
21. Huber A., Feldman B.M. Long-term outcomes in juvenile dermatomyositis: how did we get here and where are we going?. Curr Rheumatol Rep 2005, 7:441-446.
22. Huber A.M., Feldman B.M., Rennebohm R.M., et al. Validation and clinical significance of the childhood myositis assessment scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies. Arthritis Rheum 2004, 50:1595-1603.
23. Kendall F.P., McCreary E.K., Provance P.G. Muscles: Testing and Function 1993, Williams and Wilkins, Baltimore. 4th edn.
24. Kim B., Kaistha S.D., Rouse B.T. Viruses and autoimmunity. Autoimmunity 2005, 38:559-565.
25. Kim K.S., El-Hallak M., Dedeoglu F., et al. Complete and sustained remission of juvenile dermatomyositis resulting from aggressive treatment. Arthritis Rheum 2009, 60:1825-1830.
26. López de Padilla C.M., Vallejo A.N., McNallan K.T., et al. Plasmacytoid dendritic cells in inflamed muscle of patients with juvenile dermatomyositis. Arthritis Rheum 2007, 56:1658-1668.
27. Lovell D.J., Lindsley C.B., Rennebohm R.M., et al. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. II. The Childhood Myositis Assessment Scale (CMAS): A quantitative tool for the evaluation of muscle function. Arthritis Rheum 1999, 42:2213-2219.
28. McCann L.J., Juggins A.D., Maillard S.M., et al. The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland): clinical characteristics of children recruited within the first 5 years. Rheumatology 2006, 45:1255-1260.
29. Meng C., Adler R., Peterson M., et al. Combined use of power Doppler and gray-scale sonography: a new technique for the assessment of inflammatory myopathy. J Rheumatol 2001, 28:1271-1282.
30. Molina V., Shoenfeld Y. Infection, vaccines and other environmental triggers of autoimmunity. Autoimmunity 2005, 38:235-245.
31. Niewold T.B., Kariuki S.N., Morgan G.A., et al. Elevated serum interferon-alpha activity in juvenile dermatomyositis: associations with disease activity at diagnosis and after thirty-six months of therapy. Arthritis Rheum 2009, 60:1815-1824.
32. Oddis C.V., Conte C.G., Steen V.D., et al. Incidence of polymyositis-dermatomyositis - a 20 years study of hospital diagnosed cases in Allegheny County, PA 1963-1982. J Rheumatol 1990, 17:1329-1334.
33. Pachman L.M., Hayford J.R., Hochberg M.C. Seasonal onset in juvenile dermatomyositis [JDMS]: an epidemiological study. Arthritis Rheum 1992, 35:S88.
34. Pachman L.M., Hayford J.R., Chung A. Juvenile dermatomyositis at diagnosis: clinical characteristics of 79 children. J Rheumatol 1998, 25:1198-1204.
35. Pachman L.M., Liotta-Davis M.R., Hong D.K., et al. TNFalpha-308A allele in juvenile dermatomyositis: association with increased production of tumor necrosis factor alpha, disease duration, and pathologic calcifications. Arthritis Rheum 2000, 43:2368-2377.
36. Park J.H., Olsen N.J. Utility of magnetic resonance imaging in the evaluation of patients with inflammatory myopathies. Curr Rheumatol Rep 2001, 3:334-345.
37. Pilkington C. Clinical assessment in juvenile idiopathic inflammatory myopathies and the development of disease activity and damage tools. Curr Opin Rheumatol 2004, 16:673-677.
38. Pilkington C., Owen N.J., Bose S., et al. A preliminary comparative study of high frequency muscle ultrasound and magnetic resonance imaging in 7 patients with juvenile dermatomyositis. Ann Rheum Dis 2000, 59:727-728.
39. Ramanan A.V., Feldman B.M. Clinical outcomes in juvenile dermatomyositis. Curr Opin Rheumatol 2002, 14:658-662.
40. Reed A.M., Ytterberg S.R. Genetic and environmental risk factors for idiopathic inflammatory myopathies. Rheum Dis Clin North Am 2002, 28:891-916.
41. Rider L.G. Idiopathic inflammatory myopathies. Rheum Dis Clin North Am 2002, 28:1-41.
42. Rider L.G., Feldman B.M., Perez M.D., et al. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies: I. Physician, parent, and patient global assessments. Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Arthritis Rheum 1997, 40:1976-1983.
43. Ruperto N., Ravelli A., Murray K.J., et al. Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. Rheumatology (Oxford) 2003, 42:1452-1459.
44. Santiago R.A., Silva C.A., Caparbo V.F., et al. Bone mineral apparent density in juvenile dermatomyositis: the role of lean body mass and glucocorticoid use. Scand J Rheumatol 2008, 37:40-47.
45. Scheja A., Elborgh R., Wildt M. Decreased capillary density in juvenile dermatomyositis and in mixed connective tissue disease. J Rheumatol 1999, 26:1377-1381.
46. Symmons D.P., Sills J.A., Davis S.M. The incidence of juvenile dermatomyositis: results from a nation-wide study. Br J Rheumatol 1995, 34:732-736.
47. Targoff I.N., Mamyrova G., Trieu E.P., et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum 2006, 54:3682-3689.
48. Wedderburn L.R., Varsani H., Li C.K.C., et al. International consensus on a proposed score system for muscle biopsy evaluation in patients with JDM, for potential use in clinical trials. Arthritis Rheum 2007, 57:1192-1201.